Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Phase 3TerminatedNCT00599820

Asociación para Evitar la Ceguera en México

Overview

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Angioid Streaks Choroidal Neovascularization

Interventions

Intravitreal BevacizumabDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of Angioid Streaks * Choroidal neovascularization associated * Untreated patients or patients treated once with PDT Exclusion Criteria: * Ocular surgery excepting uncomplicated phacoemulsification * Glaucoma or any other ocular pathology

Locations (1)

Asociación para Evitar la Ceguera en México (APEC)

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

BCVA

Fluoresceine Angiography

Optical Coherence Tomography

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.